Multiple Dialogues of MS

Welcome to BiogenTalks and Multiple Dialogues of MS. Podcasts are intended for Healthcare Professionals only. Please do not share or distribute. This podcast series contains interviews with some of the world-leading experts in Multiple Sclerosis. In each episode you will receive useful information and advice on important themes and relevant questions.

Professor Dr. Bart van Wijmeersch:

Walking impairment in Multiple Sclerosis (MS): Symptoms, evaluation, and the role of exercise.

Professor Dr. Bart van Wijmeersch:

Walking impairment in Multiple Sclerosis (MS): The latest research.

Professor Gabriel Pardo:

Sequencing therapies in Multiple Sclerosis: Opportunities and strategic thinking.

Professor Gabriel Pardo:

Sequencing therapies in Multiple Sclerosis: Managing patients throughout the disease journey.

Professor Carlo Tornatore and Dr. Wallace Brownlee:

MS treatment in the era of COVID-19 (part 1): Disease management, virtual consultations and the global data sharing initiative.

Professor Carlo Tornatore and Dr. Wallace Brownlee:

MS treatment in the era of COVID-19 (part 2): Immunology, vaccination readiness and the upcoming flu season.

Professor Thomas Berger:

Understanding the effects of MS treatment with patient-reported outcomes (PROs).

Professor Dr. Stefan Braune:

Personalized medicine in multiple sclerosis (MS).

Professor Dr. Tomas Kalincik and Professor Dr. Richard Nicholas:

Pearls and pitfalls of real-world evidence (RWE).

Professor Dr. Tomas Kalincik and Professor Dr. Richard Nicholas:

How can we improve real-world data collection in multiple sclerosis (MS)?

Dr. Orla Gray and Dr. Owen Pearson:

What does the future in RWE look like?

Nurse Practitioner Trudy Campbell:

Nursing strategies to improve MS patients´ adherence and persistence.

Professor Ralf Gold:

Key Learnings from up to 13 years of follow-up with TECFIDERA® (dimethyl fumarate) treatment experience.

Professor Ralf Gold:

Safety data from up to 13 years of long-term follow-up with TECFIDERA® (dimethyl fumarate) treatment.

Biogen-105037.
Date of preparation: May 2021.